Advanced Proteome Th (APTCF) 0.2004 $APTCF
Advanced Proteome Therapeutics' Lead Compound Inhibits Metastasis in Breast Cancer Tumor Model
Marketwired - Wed Apr 29, 11:47AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce that its current lead compound APC 101 successfully diminished the frequency of tumor metastasis in the 4T1 animal model.
APC.VN: 0.225 (-0.010)
Advanced Proteome Therapeutics Reports Successful Fusion Protein Initiative Resulting in APC 103 Which Retards Tumor Growth in an Animal Model
Marketwired - Mon Apr 27, 8:02AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce that its new fusion protein, APC 103, exhibited enhanced activity over the parent protein in retarding tumor growth in animal studies, comparable to APC 101 which has been the Company's principal point of focus to date.
APC.VN: 0.225 (-0.010)
Advanced Proteome Therapeutics Corporation Announces Issuance of a New U.S. Patent for Modifying Proteins to Enhance Their Biological Activities
Marketwire Canada - Mon Apr 13, 8:17AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) (FRANKFURT: 0E8) wishes to announce that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8927485, which has been assigned to the Company. The invention is directed toward bundling two or more entities together to increase the biological activity of the individual entities. This type of approach in the industry has been key to developing new generations of anti-cancer drugs and diverse therapeutics. The modifications described can be used for the production and application of the bundled entities in the treatment of disorders such as rheumatoid arthritis and various autoimmune diseases, type-1 diabetes, and cancer. The patent, which expires in 2035, claims methods for the site-specific modification of peptides, polypeptides, and proteins, all of which represent species of viable therapeutics. The patent has been filed under the title of "Site-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides" to emphasize the breadth of its utility.
APC.VN: 0.225 (-0.010)
Advanced Proteome Therapeutics Announces Promising Results of Triple Combination Immunotherapy Tests
ACCESSWIRE - Tue Apr 07, 6:16PM CDT
VANCOUVER, BC / ACCESSWIRE / April 7, 2015 / Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) (0E8.F) is pleased to announce the first results of testing a triple combination of immunotherapies in animal models. These preliminary tests were carried out in conjunction with its academic collaborators.
APC.VN: 0.225 (-0.010)
Advanced Proteome Therapeutics Appoints Dr. David Webb to its Corporate Advisory Board
ACCESSWIRE - Mon Mar 30, 8:05AM CDT
VANCOUVER, BC / ACCESSWIRE / March 30, 2015 / Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) (0E8.F) is pleased to announce that its Board of Directors has appointed Dr. David Webb to the Company's Corporate Advisory Board.
APC.VN: 0.225 (-0.010)
Advanced Proteome Therapeutics Provides Corporate Update on Multiple Activities
Marketwired - Mon Mar 23, 11:46AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to provide the following corporate update to its shareholders.
APC.VN: 0.225 (-0.010)
In an Exclusive Interview the CEO of Advanced Proteome Therapeutics (APC) Discusses the Company's Technology and R&D Strategy
Marketwired - Thu Jan 29, 10:19AM CST
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) (FRANKFURT: 0E8) announces that APC was profiled in a BioTuesdays.com interview with Leonard Zehr. In the interview, encompassing a wide range of topics, the CEO, Dr. Allen Krantz, discussed the Company's unique approach to developing a potential anti-cancer therapeutic. Dr. Krantz alluded to advantages of the technology, which is designed to combine multiple anti-cancer therapies in a single agent. He pointed out that the agent is not only intended to directly target tumors, but to stimulate the immune system and, in combination with other immunotherapeutic agents, such as the very exciting checkpoint inhibitors, achieve greater overall response rates and durable responses in patients than are currently being observed in the clinic.
APC.VN: 0.225 (-0.010)
Advanced Proteome Therapeutics Engages CRO to Escalate Testing of Promising Cancer Therapy
Marketwired - Wed Nov 12, 12:34PM CST
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC)(FRANKFURT: 0E8) is pleased to announce that it has entered into an agreement with one of the world's foremost contract research organizations (CRO). Now, in addition to its in-house programs and academic collaborations, APC will be able to avail itself of the CRO's high quality research models and preclinical and clinical support services to evaluate and accelerate the Company's immuno-oncology program.
APC.VN: 0.225 (-0.010)
APC Announces Positive Results in Combination Cancer Immunotherapy
Marketwire - Thu Sep 11, 8:02AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) (FRANKFURT: 0E8) is excited to report results from its current round of experiments that not only reinforce previous evidence of the immunotherapeutic properties of APC's protein modification technology, but hold forth the possibility of synergistic effects with other immunotherapies while heralding the entry of a new and potentially powerful approach in the arsenal of anticancer weaponry.
APC.VN: 0.225 (-0.010)
Advanced Proteome Therapeutics Expands Anticancer Studies Base D on Strong Initial Results
Marketwire - Tue Aug 12, 8:28AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC)(FRANKFURT: 0E8) is pleased to announce that it has expanded and accelerated its anticancer studies to strengthen their commercial prospects because recent positive results with collaborators have demonstrated that modifications of APC's protein delivery system substantially increases antitumor activity and retards tumor growth in animals.
APC.VN: 0.225 (-0.010)
Advanced Proteome Therapeutics' Lead Compound Inhibits Metastasis in Breast Cancer Tumor Model
Marketwired - Wed Apr 29, 11:47AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce that its current lead compound APC 101 successfully diminished the frequency of tumor metastasis in the 4T1 animal model. APC.VN: 0.225 (-0.010)
Advanced Proteome Therapeutics Reports Successful Fusion Protein Initiative Resulting in APC 103 Which Retards Tumor Growth in an Animal Model
Marketwired - Mon Apr 27, 8:02AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce that its new fusion protein, APC 103, exhibited enhanced activity over the parent protein in retarding tumor growth in animal studies, comparable to APC 101 which has been the Company's principal point of focus to date. APC.VN: 0.225 (-0.010)
Advanced Proteome Therapeutics Corporation Announces Issuance of a New U.S. Patent for Modifying Proteins to Enhance Their Biological Activities
Marketwire Canada - Mon Apr 13, 8:17AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (FRANKFURT: 0E8) wishes to announce that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8927485, which has been assigned to the Company. The invention is directed toward bundling two or more entities together to increase the biological activity of the individual entities. This type of approach in the industry has been key to developing new generations of anti-cancer drugs and diverse therapeutics. The modifications described can be used for the production and application of the bundled entities in the treatment of disorders such as rheumatoid arthritis and various autoimmune diseases, type-1 diabetes, and cancer. The patent, which expires in 2035, claims methods for the site-specific modification of peptides, polypeptides, and proteins, all of which represent species of viable therapeutics. The patent has been filed under the title of "Site-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides" to emphasize the breadth of its utility. APC.VN: 0.225 (-0.010)
Advanced Proteome Therapeutics Announces Promising Results of Triple Combination Immunotherapy Tests
ACCESSWIRE - Tue Apr 07, 6:16PM CDT
VANCOUVER, BC / ACCESSWIRE / April 7, 2015 / Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (0E8.F) is pleased to announce the first results of testing a triple combination of immunotherapies in animal models. These preliminary tests were carried out in conjunction with its academic collaborators. APC.VN: 0.225 (-0.010)
Advanced Proteome Therapeutics Appoints Dr. David Webb to its Corporate Advisory Board
ACCESSWIRE - Mon Mar 30, 8:05AM CDT
VANCOUVER, BC / ACCESSWIRE / March 30, 2015 / Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (0E8.F) is pleased to announce that its Board of Directors has appointed Dr. David Webb to the Company's Corporate Advisory Board. APC.VN: 0.225 (-0.010)
Advanced Proteome Therapeutics Provides Corporate Update on Multiple Activities
Marketwired - Mon Mar 23, 11:46AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to provide the following corporate update to its shareholders. APC.VN: 0.225 (-0.010)
In an Exclusive Interview the CEO of Advanced Proteome Therapeutics (APC) Discusses the Company's Technology and R&D Strategy
Marketwired - Thu Jan 29, 10:19AM CST
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (FRANKFURT: 0E8) announces that APC was profiled in a BioTuesdays.com interview with Leonard Zehr. In the interview, encompassing a wide range of topics, the CEO, Dr. Allen Krantz, discussed the Company's unique approach to developing a potential anti-cancer therapeutic. Dr. Krantz alluded to advantages of the technology, which is designed to combine multiple anti-cancer therapies in a single agent. He pointed out that the agent is not only intended to directly target tumors, but to stimulate the immune system and, in combination with other immunotherapeutic agents, such as the very exciting checkpoint inhibitors, achieve greater overall response rates and durable responses in patients than are currently being observed in the clinic. APC.VN: 0.225 (-0.010)
Advanced Proteome Therapeutics Engages CRO to Escalate Testing of Promising Cancer Therapy
Marketwired - Wed Nov 12, 12:34PM CST
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC)(FRANKFURT: 0E8) is pleased to announce that it has entered into an agreement with one of the world's foremost contract research organizations (CRO). Now, in addition to its in-house programs and academic collaborations, APC will be able to avail itself of the CRO's high quality research models and preclinical and clinical support services to evaluate and accelerate the Company's immuno-oncology program. APC.VN: 0.225 (-0.010)
APC Announces Positive Results in Combination Cancer Immunotherapy
Marketwire - Thu Sep 11, 8:02AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (FRANKFURT: 0E8) is excited to report results from its current round of experiments that not only reinforce previous evidence of the immunotherapeutic properties of APC's protein modification technology, but hold forth the possibility of synergistic effects with other immunotherapies while heralding the entry of a new and potentially powerful approach in the arsenal of anticancer weaponry. APC.VN: 0.225 (-0.010)
Advanced Proteome Therapeutics Expands Anticancer Studies Base D on Strong Initial Results
Marketwire - Tue Aug 12, 8:28AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC)(FRANKFURT: 0E8) is pleased to announce that it has expanded and accelerated its anticancer studies to strengthen their commercial prospects because recent positive results with collaborators have demonstrated that modifications of APC's protein delivery system substantially increases antitumor activity and retards tumor growth in animals. APC.VN: 0.225 (-0.010)
